Completed PHASE1/PHASE2 NCT00124943

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

Sponsor: Celgene Corporation

Conditions Coronary Restenosis

Interventions Nanoparticle Paclitaxel

Updated 6 times since 2017 Last updated: Mar 28, 2012 Started: Jul 31, 2005 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

Listed as NCT00124943, this PHASE1/PHASE2 trial focuses on Coronary Restenosis and remains completed. Sponsored by Celgene Corporation, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.